• Medical Case: An unexplained shortness of breath, and a surprising discovery

    An 82-year-old patient complains of severe shortness of breath and other symptoms, and the cause remains unclear at first. What could be behind these symptoms?

  • Fibrodysplasia ossificans progressiva, a rare genetic disorder

    FOP is a rare genetic disorder where soft tissues turn into bone, limiting movement and causing severe complications, with an average life expectancy of 40 years.

  • Rare diseases are no longer just a curiosity

    Rare diseases evolved from anomalies to recognized conditions, with key advances in genetics, treatment, and global initiatives.

  • Fabry disease in paediatric patients

    Pediatric FD poses a complex clinical challenge, with early symptoms, progressive multiorgan involvement, and diagnostic delays. Early diagnosis and intervention are key.

  • A chatbot that knows more than a doctor?

    A study shows that AI outperforms doctors in complex diagnoses. However, integrating it into medical practice requires more than just technology.

  • Neuroprosthetic communication in ALS

    An article published in the NEJM presents new technologies that could restore communication in ALS: a breakthrough for paralysed patients.

  • Antibiotics: risky during pregnancy and early childhood?

    The study used data from over three million children and focused on autism spectrum disorders, intellectual developmental delays, language development disorders and epilepsy.

  • How well do cancer drugs really work?

    Only a third of USA-approved oncology drugs seem to improve overall survival. This is the sobering conclusion of a retrospective analysis of US approvals.

  • PAT1 deficiency: the latest on the intestinal barrier and inflammatory bowel disease

    The deficiency of the anion transporter PAT1 leads to a disrupted intestinal barrier, microbial dysbiosis and increased susceptibility to intestinal inflammation.

  • Difficult-to-treat RA: Which drugs are most effective?

    Rheumatoid arthritis treatment is often complex. If patients do not respond to therapy, the question arises as to which drugs can help.

  • Medical Case: A rare of jaundice in a farmer

    62-year-old woman with fatigue, jaundice, fever, and kidney injury. Can you guess the diagnosis?

  • HFpEF: a focus on therapeutic strategies

    No available medical therapy has resulted in a reduction in mortality among patients with HFpEF. Therefore, the current aims of medical treatment are to reduce the risk of hospitalization and improve quality of life.

  • Medical History: The tragedy that gave birth to ATLS

    Dr. James Styner transformed trauma care after a 1976 plane crash, creating the ATLS protocol (now a global benchmark) to standardize emergency treatment.

  • Post-op pain prophylaxis for endometriosis: What works best?

    Current guidelines recommend routine postoperative hormone treatment to control pain in endometriosis. But which treatment regimen is most effective?

  • Improving FCC in Neonatal ICUs

    A study shows that as a result of the “close parent intervention” program, FCC practices were improved in 8 NICUs.

  • Discussion of age limits for bowel cancer screening

    A recent cost-effectiveness analysis addressed the question of the appropriate age for the start and end of screening colonoscopies.

  • Innovations and perspectives in liver transplantation

    Liver transplantation is a rapidly developing field. Advanced technologies, like AI, will improve access, outcomes, and offer more personalized care.

  • InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

    Tafasitamab plus lenalidomide and rituximab outperformed lenalidomide plus rituximab and a placebo in patients with relapsed or refractory follicular lymphoma.

  • Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

    Auto-SCT did not improve mantle cell lymphoma with undetectable minimal residual disease outcomes after induction therapy.

  • IFM2017-03: Daratumumab therapy fruitful for frail patients with MM

    Daratumumab plus lenalidomide had superior PFS outcomes vis-a-vis lenalidomide plus dexamethasone in frail patients with untreated MM.

  • 1 |
  • 2 |
  • 3 |
  • 4 |
  • 5 |
  • 6 |
  • 7 |